Sugi Predict

Sugi Predict / Compounds / SCHEMBL1151035

SCHEMBL1151035

SCHEMBL1151035

CN1CCC(n2ccn3c(=O)c(O)c(-c4ncc(Cc5ccc(F)cc5)s4)nc23)C1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ GAA P10253 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ CCR6 P51684 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ HSD17B2 P37059 1/20 0.33
▸ GLA P06280 1/20 0.32
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1150957 0.84 SMN1; SMN2 (0.40) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL1151351 0.80 SMN1; SMN2 (0.39) SMN1; SMN2NPC1RAB9AKDM4EMEN1
SCHEMBL1150882 0.78 RAB9A (0.36) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL1151024 0.78 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL12862300 0.77 GRIN2B (0.39) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL13522716 0.77 GRIN2B (0.34) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL1150416 0.77 SMN1; SMN2 (0.37) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL12862323 0.77 GRIN2B (0.39) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL1150415 0.77 SMN1; SMN2 (0.37) SMN1; SMN2GAAOPRK1CCR6NPSR1
SCHEMBL12862245 0.77 GRIN2B (0.39) SMN1; SMN2GAAOPRK1CCR6NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291377-B1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LTD (AU) 2015-02-18 — — EP disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-8431581-B2 Imidazopyrimidines and uses thereof AVEXA LIMITED (AU) 2013-04-30 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF AVEXA LIMITED (AU) 2011-02-03 — — US disclosed
WO-2010000031-A1 IMIDAZOPYRIMIDINONES AND USES THEREOF AVEXA LIMITED (AU) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028487-A1 IMIDAZOPYRIMIDINES AND USES THEREOF TPMT, DPYD, IMPDH1 SMN1; SMN2 958/4885GAA 453/4885OPRK1 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.